Select Country

 
877-783-6728 (877-StemSave)

StemSave Blog

Lymphoma Treatment Utilizing Stem Cells Receives FDA Approval

Posted by maxi@stemsave.com on May 4, 2018 1:08:00 PM

A genetically modified stem cell therapy for Diffuse Large B-Cell Lymphoma (DLBCL) has been approved by the FDA. Researchers at the Abramson Cancer Center, in collaboration with Novartis, have successfully administered a CAR-T Cell therapy, called Kymriah, for the most common type of non-Hodgkin Lymphoma. DLBCL is a fast growing cancer that affects B lymphocytes, which are responsible for producing antibodies that help fight infections in the body. This groundbreaking treatment involves obtaining autologous (the patient’s own) T cells, which are a more specialized type of stem cell, and genetically engineering the cells to track down and destroy cancerous cells. 

Read More

Topics: stem cell therapy, cancer treatment, lymphoma

AAOMS

AAOMS - American Association of Oral and Maxillofacial Surgeons

 

As the industry leader, StemSave is the only stem cell banking service to be designated as an ASI approved program.

Subscribe to Email Updates

Join our Newsletter

Recent Posts

Posts by Topic

see all